EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

10 Years Since the LIR!C Trial: Old News or New Beginnings?

Paul Griebel

JCC Plus · 2026-11 · 1 (6)

DOI: 10.1002/jcc5.70102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCC Plus, online erschienen am 14.11.2026. Verfasst von Paul Griebel. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Crohn's and Colitis Organisation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In many patients with Crohn's disease, disease is initially confined to the ileocaecal region. The landmark LIR!C trial published in 2017 demonstrated that in localised ileocaecal disease refractory to standard immunomodulating therapy, primary ileocaecal resection led to similar outcomes concerning quality of life and remission as therapy with infliximab. After 5 years, 42% of patients in the resection group remained therapy‐free whereas 48% in the infliximab arm had to undergo a Crohn's disease related resection. This Y‐ECCO review highlights and discusses the results of the recently published study by Oldenburg, Haanappel and colleagues, providing long‐term follow‐up data of this landmark trial. They were able to follow up on 129 of 143 patients (90%) to the 10‐year mark after treatment initiation. Therapy‐free remission rate was significantly higher in the ileocaecal resection group compared to the infliximab group (36% vs. 13%; p = 0.0038), whereas clinical remission rates were comparable (36% vs. 29%; p = 0.31). 36 patients (57%) in the infliximab group had to undergo ileocaecal resection throughout the course of their disease. Higher age and presence of perianal disease were identified as potential predictors for additional therapy in the resection group. These findings support recent guideline changes, recommending primary surgery in localised ileocaecal disease as an alternative to biologic therapy with comparable outcomes in terms of clinical remission and higher therapy‐free remission rates after 10 years compared with infliximab.

Förderung

  • European Crohn's and Colitis Organisation

Zitieren

APA

Griebel, P. (2026). 10 Years Since the LIR!C Trial: Old News or New Beginnings?. JCC Plus, 1(6). https://doi.org/10.1002/jcc5.70102

Vancouver

Griebel P. 10 Years Since the LIR!C Trial: Old News or New Beginnings?. JCC Plus. 2026;1(6). doi:10.1002/jcc5.70102

BibTeX
@article{Griebel2026,
  author = {Griebel, Paul},
  title = {10 Years Since the LIR!C Trial: Old News or New Beginnings?},
  journal = {JCC Plus},
  year = {2026},
  volume = {1},
  number = {6},
  doi = {10.1002/jcc5.70102}
}
Kostenlos starten →